Related Experiment Video
Updated: Jun 4, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Resource utilization with insulin pump therapy for type 2 diabetes mellitus
Peter M Lynch1, Aylin Altan Riedel, Navendu Samant
1Medtronic, Inc, 18000 Devonshire St, Northridge, CA 91325, USA. peter.m.lynch@medtronic.com
The American Journal of Managed Care
|February 26, 2011
Summary
Switching to continuous subcutaneous insulin infusion (CSII) significantly reduced antidiabetic drug use and healthcare visits for type 2 diabetes patients on multiple daily injections (MDI). This therapy offers a stable care option.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacoeconomics
Background:
- Multiple daily injection (MDI) therapy is common for type 2 diabetes management.
- High antidiabetic drug and healthcare resource utilization can indicate suboptimal glycemic control or treatment burden.
Purpose of the Study:
- To evaluate the impact of transitioning from MDI to continuous subcutaneous insulin infusion (CSII) on antidiabetic medication use.
- To assess changes in healthcare resource utilization following CSII initiation.
Main Methods:
- Retrospective analysis of administrative claims data from a large US health plan (2005-2008).
- Comparison of antidiabetic drug use and healthcare utilization before and after CSII initiation in 943 patients.
- Statistical analysis using paired t-tests to determine significance.
Main Results:
- CSII initiation led to a 46% decrease in the mean number of antidiabetic drugs used and a 58% reduction in patients using multiple antidiabetic drugs.
- Over one-third of patients discontinued oral antidiabetic agents post-CSII initiation.
- Significant decreases in emergency department visits and inpatient admissions, alongside an increase in ambulatory visits, were observed.
Conclusions:
- Continuous subcutaneous insulin infusion (CSII) is associated with reduced antidiabetic drug and healthcare resource utilization, promoting care stability.
- CSII represents a viable therapeutic option for type 2 diabetes patients on MDI experiencing high treatment burden.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:36Carbohydrate Metabolism
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...